MONTROUGE, France, April 7, 2016 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced today its full year 2015 results. Audit procedures on the Company's 2015 consolidated financial statements were completed by the Company's statutory auditors. The issuance of the audit report is pending.
Full year 2015 results
Selected financial information (IFRS consolidated financial statements)
|In million euros||2014||2015|
|Research and development expenses||(21.1)||(34.2)|
|General and administrative expenses||(8.1)||(16.9)|
|Operating profit (loss)||(24.6)||(45.6)|
|Net profit (loss)||(24.0)||(44.7)|
|EPS (in € per share)||(1.49)||(2.08)|
|Net cash flows from operating activities||(20.6)||(26.8)|
|Net cash flows from financing activities||96.8||241.0|
|Net cash flows||75.2||208.9|
|Cash and cash equivalents at closing||114.6||323.4|
The Company's total income increased by 29.5 % from €4.8 million in 2014 to €6.2 million in 2015. These revenues were primarily in the form of research tax credit (Crédit Impôt Recherche) and other government subsidies, and to a lesser extent, generated from sales of Diallertest®. Sales of Diallertest® decreased to K€202 in 2015 compared with K€211 a year earlier, as the Company terminated its commercial partnership related to the sale of Diallertest® during the second half of 2015.
Research and Development expenses increased by 61.9 % from €21.1 million in 2014 to €34.2 million in 2015. This increase reflects increased research and development activity, both on the pre-clinical research and clinical development fronts, as well as the hiring of additional research and development personnel to support these activities.
General and administrative expenses increased by 108 % from €8.1 million in 2014 to €16.9 million in 2015. This increase resulted from increased general and administrative headcount to support the Company's continued growth, increased audit fees related to the Company's listing on the NASDAQ Stock Market and Sarbanes-Oxley compliance and increased legal and consultant fees.
The Company's net loss in 2015 amounted to €(44.7) million compared with €(24.0) million in 2014. The loss per share (based on the weighted average number of shares outstanding over the period) amounted to €(2.08) and €(1.49) for 2015 and 2014, respectively.
Net cash flows from operating activities in 2015 and 2014 were €(26.8) million and €(20.6) million, respectively, primarily as a result of increased research and development activity.
Net cash flows from financing activities increased to €241.0 million in 2015 compared with €96.8 million a year earlier, primarily as a result of the net proceeds of our underwritten public offering of ordinary shares in the form of American Depositary Shares completed in July 2015.
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release contains forward-looking statements, including statements reflecting management's expectations for future financial and operational performance and business outlook; and statements regarding our research and development efforts and the commercial potential of our product candidates generally. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2014 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.
|DBV Technologies Contact|
| Susanna Mesa |
Senior Vice President, Strategy
Tel. : +1 212-271-0861
|DBV Technologies Media Contacts US & Europe|
| Marion Janic |
Rooney & Associates
Tel. : +1-212-223-4017
Tel. : +1-646-722-8822
| Caroline Carmagnol |
Alize RP - Relation Presse
Tel. : +33(0)6 64 18 99 59
PDF Version http://hugin.info/156437/R/2001107/738276.pdf